Pharsight

IPSEN BIOPHARM patents facing oppositions

Top patents of IPSEN BIOPHARM facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3266456B1 05 May, 2021 Combinations of liposomal irinotecan, 5-fu and leucovorin for the treatment of pancreatic cancer Jun, 2033 3
EP3337478B1 12 Aug, 2020 Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer Aug, 2036 2
EP2939688B1 Pharmaceutical compositions comprising botulinum neurotoxin NA 1
EP3337467B1 09 Dec, 2020 Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment Aug, 2036 1